Can contrast-enhanced US with targeted microbubbles monitor the response to antiangiogenic therapies?
Kruskal
Jonathan B
JB
Department of Radiology, Beth Israel Deaconess Medical Center, One Deaconess Rd, Boston, MA 02215, USA. jkruskal@bidmc.harvard.edu
D000700:Analgesics / Q000008:administration & dosage; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D003287:Contrast Media; D016503:Drug Delivery Systems / Q000379:methods; D007089:Image Enhancement / Q000379:methods; D051379:Mice; D045423:Microbubbles; D009369:Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000378:metabolism; D011379:Prognosis; D014463:Ultrasonography / Q000379:methods*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000378:metabolism*
D000700:Analgesics; D020533:Angiogenesis Inhibitors; D003287:Contrast Media; D040301:Vascular Endothelial Growth Factor Receptor-2